These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35345850)

  • 1. Prevention of Triglyceridemia by (Non-)Anticoagulant Heparin(oids) Does Not Preclude Transplant Vasculopathy and Glomerulosclerosis.
    Shrestha P; Katta K; Talsma D; Naggi A; Hillebrands JL; van de Sluis B; van den Born J
    Front Cell Dev Biol; 2022; 10():798088. PubMed ID: 35345850
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats.
    Waanders F; Rienstra H; Boer MW; Zandvoort A; Rozing J; Navis G; van Goor H; Hillebrands JL
    Am J Physiol Renal Physiol; 2009 May; 296(5):F1072-9. PubMed ID: 19244402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased migration of antigen presenting cells to newly-formed lymphatic vessels in transplanted kidneys by glycol-split heparin.
    Talsma DT; Katta K; Boersema M; Adepu S; Naggi A; Torri G; Stegeman C; Navis G; van Goor H; Hillebrands JL; Yazdani S; van den Born J
    PLoS One; 2017; 12(6):e0180206. PubMed ID: 28665959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats.
    Rienstra H; Katta K; Celie JW; van Goor H; Navis G; van den Born J; Hillebrands JL
    PLoS One; 2010 Feb; 5(2):e9095. PubMed ID: 20140097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding.
    Adepu S; Rosman CW; Dam W; van Dijk MC; Navis G; van Goor H; Bakker SJ; van den Born J
    Am J Physiol Renal Physiol; 2015 Jul; 309(2):F137-45. PubMed ID: 25972509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic syndecan-1 changes associate with dyslipidemia after renal transplantation.
    Adepu S; Katta K; Tietge UJ; Kwakernaak AJ; Dam W; van Goor H; Dullaart RP; Navis GJ; Bakker SJ; van den Born J
    Am J Transplant; 2014 Oct; 14(10):2328-38. PubMed ID: 25154787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction.
    Vavrincova-Yaghi D; Deelman LE; van Goor H; Seelen MA; Vavrinec P; Kema IP; Gomolcak P; Benigni A; Henning RH; Sandovici M
    Gene Ther; 2016 Nov; 23(11):797-806. PubMed ID: 27454318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma PCSK9 levels correlate with cholesterol in men but not in women.
    Mayne J; Raymond A; Chaplin A; Cousins M; Kaefer N; Gyamera-Acheampong C; Seidah NG; Mbikay M; Chrétien M; Ooi TC
    Biochem Biophys Res Commun; 2007 Sep; 361(2):451-6. PubMed ID: 17645871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure.
    Albrecht EW; van Goor H; Smit-van Oosten A; Stegeman CA
    Nitric Oxide; 2003 Feb; 8(1):53-8. PubMed ID: 12586542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of heparin-binding protein increasing vascular permeability in early burn].
    Song M; Liu L; Qi X; Yang Y; Huang J; Sun R; Sun B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Mar; 32(3):330-335. PubMed ID: 32385998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum homocysteine levels in renal transplant recipients with and without hypercholesterolemia.
    Piovesan F; Veronese FJ; Santos AF; Pozza R; Sarturi PS; Tognon A; Garcia VD; Keitel E; Saitovitch D
    Arq Bras Cardiol; 2007 Sep; 89(3):154-9, 170-5. PubMed ID: 17906816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.
    Frank-Kamenetsky M; Grefhorst A; Anderson NN; Racie TS; Bramlage B; Akinc A; Butler D; Charisse K; Dorkin R; Fan Y; Gamba-Vitalo C; Hadwiger P; Jayaraman M; John M; Jayaprakash KN; Maier M; Nechev L; Rajeev KG; Read T; Röhl I; Soutschek J; Tan P; Wong J; Wang G; Zimmermann T; de Fougerolles A; Vornlocher HP; Langer R; Anderson DG; Manoharan M; Koteliansky V; Horton JD; Fitzgerald K
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11915-20. PubMed ID: 18695239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
    Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
    Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of proteinuria and focal-segmental glomerulosclerosis in recipients of pediatric donor kidneys.
    Hayes JM; Steinmuller DR; Streem SB; Novick AC
    Transplantation; 1991 Nov; 52(5):813-7. PubMed ID: 1949166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.